[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618429":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":34,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":73,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Oncoliq US Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Breast Cancer Cohort",null,"Participants with a confirmed diagnosis of breast cancer, prior to surgery or systemic treatment.",[13],"Other: Peripheral blood draw",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy Control Cohort","Cancer-free volunteers confirmed by breast imaging (BI-RADS 1 or 2) and without a prior history of cancer.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Peripheral blood draw","Collection of a blood sample for plasma isolation and miRNA analysis.",[9,15],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Adriana De Siervi, PhD in Molecular Biology","CONTACT","+54 11 3269 5832","adesiervi@oncoliq.bio",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Camila Zaslavsky, Pharmacist","+54 11 2164 1626","camila@oncoliq.bio",[35],{"facility":36,"status":37,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":10,"geoPoint":10,"contacts":42},"DIM Centros de Salud","RECRUITING","Buenos Aires","B1704","Argentina","AR",[43],{"name":44,"role":27,"phone":45,"phoneExt":10,"email":46},"Maria Abril Acosta, Oncologist","+54 11 6376-7387","acostamariaabril@gmail.com",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100618429","validation-of-the-oncoliq-test-for-the-early-detection-of-breast-cancer-100618429",false,"NCT07331506","Validation of the Oncoliq Test for the Early Detection of Breast Cancer.","Inclusion Criteria:\n\nGroup 1 - Breast Cancer:\n\nAge between 40 and 70 years Diagnosis of breast cancer at any stage No prior surgical treatment No prior antineoplastic treatment Pathology report available at the time of enrollment Signed informed consent\n\nGroup 2 - No Cancer (Control):\n\nAge between 50 and 70 years No diagnosis or personal history of any type of cancer Digital mammography and breast ultrasound showing no breast pathology (BI-RADS 1 or 2) Signed informed consent\n\nExclusion Criteria:\n\nRefusal to sign the informed consent Communication issues that hinder understanding (hearing loss, blindness, intellectual disability, or dementia) Venipuncture for blood collection impracticable or posing a risk Personal history of previous cancer",true,"FEMALE","40 Years","70 Years",{"count":60,"type":61},300,"ESTIMATED","OBSERVATIONAL","Cancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly. However, the lack of accessible, low-cost, non-invasive, non-toxic, and easy-to-implement diagnostic methods results in late diagnoses, leading to 1 in every 6 people dying from cancer today.\n\nMicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are found both inside cells and in bodily fluids such as blood and urine. Several studies have demonstrated their role in human diseases, especially cancer, where tumors release miRNAs into the bloodstream that can be used as biomarkers for early detection.\n\nThe research and development team at Oncoliq SAS identified a panel of miRNAs associated with breast cancer, with a detection performance of 82% sensitivity and 83% specificity, validated in exploratory and preliminary confirmatory studies. These results led to the filing of a patent based on liquid biopsy technology.\n\nThe objective of this protocol is to establish a panel of miRNAs for the early detection of breast cancer using samples from breast cancer patients and a cancer-free control group. Validation of the miRNAs will be carried out through RT-qPCR. This stage constitutes the analytical validation of the biomarkers, with the goal of developing an algorithm capable of classifying individuals with and without breast cancer. In future stages, a pilot clinical trial is planned to evaluate test implementation and clinical validation.",[65,66,67,68,69,70,71,72],"Breast Cancer Detection","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Breast Cancer Female","Breast Cancer - Ductal Carcinoma in Situ (DCIS)","Breast Cancer - Infiltrating Ductal Carcinoma","Breast Cancer With Low to Intermediate HER2 Expression","Breast Cancer (Early Breast Cancer)","Breast Cancer - Female",[74,75,76,77],"Breast cancer","Detection","Liquid biopsy","miRNAs","2026-01-13",{"date":80,"type":81},"2026-01-15","ACTUAL",{"date":83,"type":81},"2025-10-17",{"date":85,"type":61},"2026-02-28",{"name":5,"class":6},1]